li001

KRAS Inhibitors and Clinical Trials Reshape Treatment Landscape for Advanced Pancreatic Cancer

Targeted Therapy /

Treatment strategies for advanced pancreatic ductal adenocarcinoma (PDAC) continue to evolve, with growing emphasis on clinical trials, biomarker-driven care, and emerging targeted therapies. Current frontline treatment remains chemotherapy-based. Patients with lower performance status are typically treated with gemcitabine alone, while fitter patients may receive combination regimens such as NALIRIFOX, FOLFIRINOX, or gemcitabine plus nab-paclitaxel. Physicians […]

KRAS Inhibitors and Clinical Trials Reshape Treatment Landscape for Advanced Pancreatic Cancer Read More »

WEE1 Inhibition Combined With Panobinostat Shows Promise in Resistant Esophageal Cancer

Research Advances /

A new study has identified an unexpected role for the WEE1 kinase in helping esophageal adenocarcinoma survive and resist chemotherapy. Researchers found that WEE1, normally known for regulating the cell cycle in the nucleus, is abnormally active in the cytoplasm of esophageal cancer cells, where it helps stabilize the cancer-driving protein c-MYC. The study showed

WEE1 Inhibition Combined With Panobinostat Shows Promise in Resistant Esophageal Cancer Read More »

Study Identifies cIAP1 as Potential Tumor Suppressor in Ewing Sarcoma

Research Advances /

A new study has identified cellular inhibitor of apoptosis protein 1 (cIAP1), encoded by the BIRC2 gene, as a potential tumor suppressor in Ewing sarcoma, a rare and aggressive pediatric cancer driven by EWSR1::FLI1 fusion proteins. Researchers analyzed gene activity across multiple Ewing sarcoma cell lines and patient datasets, finding that higher cIAP1 levels were

Study Identifies cIAP1 as Potential Tumor Suppressor in Ewing Sarcoma Read More »

FDA Approves Pivekimab sunirine-pvzy for Rare Blood Cancer BPDCN

Drug Approvals /

The FDA has approved Pivekimab sunirine-pvzy (Decnupaz) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. The drug is the first CD123-targeting antibody-drug conjugate that can be started in an outpatient setting. It is administered intravenously every three weeks based on actual body weight. Approval was supported by results

FDA Approves Pivekimab sunirine-pvzy for Rare Blood Cancer BPDCN Read More »

B7-H3–Targeted ADCs Show Promising Early Results Across Multiple Solid Tumors

Treatment /

B7-H3 is emerging as one of the most promising targets in cancer therapy because it is highly expressed across many solid tumors while remaining limited in normal tissues. Several antibody-drug conjugates (ADCs) targeting B7-H3 are now showing encouraging early results in lung, prostate, and gynecologic cancers. In small cell lung cancer, Ifinatamab deruxtecan received FDA

B7-H3–Targeted ADCs Show Promising Early Results Across Multiple Solid Tumors Read More »

FDA Approves Durvalumab Plus BCG for High-Risk Non–Muscle-Invasive Bladder Cancer

Drug Approvals /

The FDA has approved Durvalumab (Imfinzi) plus BCG for adults with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). The approval is based on the phase 3 POTOMAC trial, which compared durvalumab plus BCG against standard BCG therapy alone. The combination significantly improved disease-free survival, reducing the risk of recurrence or progression by 32% (HR 0.68; P

FDA Approves Durvalumab Plus BCG for High-Risk Non–Muscle-Invasive Bladder Cancer Read More »

Quantitative ICG Imaging Improves Perfusion Assessment and Reduces Leak Risk in Colorectal Cancer Surgery

News /

A study evaluated whether quantitative analysis of indocyanine green (ICG) fluorescence imaging could improve assessment of bowel perfusion during colorectal cancer surgery and reduce the risk of anastomotic leakage, a serious postoperative complication caused by poor blood supply at the surgical connection site. The study included 80 patients and used near-infrared imaging to assess tissue

Quantitative ICG Imaging Improves Perfusion Assessment and Reduces Leak Risk in Colorectal Cancer Surgery Read More »

Daraxonrasib Shows Practice-Changing Potential in Metastatic Pancreatic Cancer as Expanded Access Demand Surges

Treatment /

Daraxonrasib (RMC-6236), an investigational RAS(ON) inhibitor, is generating major attention in metastatic pancreatic ductal adenocarcinoma (PDAC) after positive Phase 3 RASolute 302 trial results showed significant improvements in overall survival and progression-free survival compared with standard chemotherapy. The drug has received FDA breakthrough therapy and orphan drug designations for previously treated metastatic PDAC. The results

Daraxonrasib Shows Practice-Changing Potential in Metastatic Pancreatic Cancer as Expanded Access Demand Surges Read More »

Zanidatamab Regimens Improve Survival in HER2-Positive Gastroesophageal Cancer Phase 3 Trial

Treatment /

The Phase 3 HERIZON-GEA-01 trial showed that zanidatamab-hrii (Ziihera)-based regimens significantly improved outcomes for patients with previously untreated HER2-positive advanced gastric, gastroesophageal junction, and esophageal cancers. The study enrolled 914 patients who received either zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, or standard trastuzumab plus chemotherapy. At a median follow-up of 25.9 months, both

Zanidatamab Regimens Improve Survival in HER2-Positive Gastroesophageal Cancer Phase 3 Trial Read More »

FDA Approves Decnupaz for Rare BPDCN Blood Cancer Following CADENZA Trial Results

Drug Approvals /

The FDA has approved pivekimab sunirine-pvzy (Decnupaz) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer. The first-in-class antibody-drug conjugate targets CD123 and delivers a DNA-damaging payload directly to cancer cells. Approval was based on the Phase 1/2 CADENZA trial. In treatment-naive patients, the complete remission rate reached 69.7%, with a

FDA Approves Decnupaz for Rare BPDCN Blood Cancer Following CADENZA Trial Results Read More »